Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
GlobalData on MSN1d
NHS proposes phased launch for Eli Lilly’s MounjaroThe roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback